Report of the expert meeting to update the global monitoring plan (GMP) guidance document

Transcription

1 Report of the expert meeting to update the global monitoring plan (GMP) guidance document 1. The expert meeting to update the global monitoring plan (GMP) guidance document was organized by the Secretariat of the Basel, Rotterdam and Stockholm Conventions in collaboration with the Stockholm Convention Regional Centre for Capacity Building and Technology Transfer for Central and Eastern Europe in Brno, Czech Republic, the Research Centre for Toxic Compounds in the Environment (RECETOX). The meeting was held from 7 to 9 November 2017 in Brno, Czech Republic. I. Opening of the Meeting II. 2. The meeting was declared open at 9:30 a.m. on Tuesday, 7 November The opening statements were made by Ms. Katarina Magulova, Programme Officer, Secretariat of the Basel, Rotterdam and Stockholm Conventions, and Ms. Jana Klánová, Director of RECETOX, on behalf of the local organizers. 3. The meeting was aimed at initiating the work relevant to the inclusion of the POPs listed in 2015 and in 2017 in the GMP guidance document to enable their monitoring in the third and next phases of implementation. Introduction and context A. Outcomes of COP-7 and COP-8 relevant to the update of the GMP guidance document 4. At its eighth meeting held in 2017, the Conference of the Parties to the Stockholm Convention welcomed the second global monitoring report, which marks the end of the second phase of implementation of the global monitoring plan, and requested the regional organization groups and the global coordination group to continue to implement the global monitoring plan. 5. To enable comprehensive monitoring in the third and next phases of implementation of the global monitoring plan, the monitoring guidance document needs to be amended to include considerations relevant to the POPs listed in the Convention in 2015 and Five chemicals are to be considered in the update process: i. Hexachlorobutadiene (HCBD); ii. iii. iv. Pentachlorophenol (PCP), its salts and esters; Polychlorinated naphthalenes (PCNs, di- through octa-); Decabromodiphenyl ether (decabde; BDE-209); v. Short-chain chlorinated paraffins (SCCPs, C10-C13, >48% Cl). 6. Further, three chemicals are in the process of review by the POPs Review Committee and work is to be initiated to address initial monitoring guidance considerations in the frame of the GMP for these as well: i. Dicofol; ii. iii. Pentadecafluorooctanoic acid (PFOA), its salts and PFOA-related compounds; Perfluorohexane sulfonic acid (PFHxS), its salts and PFHxS-related compounds. B. Mandate and process for updating the GMP guidance document 7. Ms. Magulova presented the overall timelines for the third phase of the GMP, including the deadlines for submission of the outputs of the third phase the third regional reports and the global report to the Conference of the Parties. In the near term, the first draft of the updated guidance document should be compiled and made available to the meeting of the regional organization groups and global coordination group to be held in May Further to the review and comments by the regional organization groups and 1

2 the global coordination group, the updated guidance document will be revised and finalized for submission at COP-9 in The timelines for the third phase of the GMP are included in the annex to this report. 8. In ensuing discussions, the need to reflect the conclusions and recommendations of the second global report throughout the GMP guidance has been highlighted. A lot of experience has been generated throughout the two phases of implementation of the GMP, and the guidance document needs to reflect concretely the present situation and include lessons learned and conclusions and recommendations of the global report in the respective relevant sections of the guidance. The guidance should provide for practical monitoring implementation directions, including most recent standard operating procedures available under monitoring programmes and the UNEP/GEF GMP2 projects (e.g. on human milk sampling). 9. Strategic considerations for future monitoring in particular for chemicals with concentrations around LOQ/LOD will also need to be addressed in the guidance. The guidance document currently lacks such considerations for sustainable monitoring on aspects such as frequency of sampling, practical and efficient use of resources and prioritization of substances/analytes for monitoring. Consideration should be given in the guidance about feasibility of monitoring of specific substances that are no longer detected in environmental and/or human samples; whether there is a need to measure everything everywhere, or rather focus only on the relevant analytes. 10. For the third monitoring reports information on the newly listed POPs should be included to the extent possible to help to decide on their relevance in view of their inclusion in regular monitoring activities and programmes for the next phases. 11. There are a number of programmes that have been and are looking at the newly listed POPs which are in the scope of the current GMP guidance update process, and it will be useful to inventory all such activities to get an idea of the frequency of monitoring of these chemicals. It will be important that regions identify specifics programmes which are not yet included in the last regional reports that can be used to provide such information. 12. The guidance should be centred on the main purpose of the GMP in support of the effectiveness evaluation, which is to show whether concentrations of POPs are decreasing over time. To achieve this result, the GMP does not need to monitor each possible congener and analyte. For the assessment of LRT which needs to go in more in depth in terms of particular substances to be addressed, it is likewise important to identify those that are relevant, prioritize according to their importance, and also rely on and use to the extent possible existing activities and projects that already look into these issues. 13. The example of the human milk survey has been given to illustrate practicability and increased user friendliness: under the UNEP/GEF GMP2 projects, more practical standard operating procedures have been developed based on the WHO protocol and are in use under the project. A concrete set of criteria for data quality should also be included in the guidance. This is particularly important as external data from national labs will be increasingly submitted to the GMP, with new countries, in particular developing countries, providing own data. To be included in the GMP, such national data need to meet strict quality criteria. III. Organizational Matters A. Adoption of the Agenda 14. The meeting participants adopted the following agenda: 1. Opening; 2. Introduction and context: a. Outcomes of COP-7 and COP-8 relevant to the update of the global monitoring plan (GMP) guidance document; b. Mandate and process for updating the GMP guidance document; 3. Experiences from monitoring programmes in sampling and analyzing the newly listed POPs in core matrices and other media: a. Hexachlorobutadiene; 2

3 b. Pentachlorophenol and its salts and esters; c. Polychlorinated naphthalenes (di- through octa-); d. Decabromodiphenyl ether; e. Short-chain chlorinated paraffins (C10-C13, >48% Cl); 4. Brainstorming on the inclusion of the newly listed POPs in the GMP guidance document: a. Identification of analytes to be monitored; b. Sampling approaches/procedures; c. Analytical approaches/procedures; 5. Way forward and workplan for updating the GMP guidance document: a. Contributors; b. Milestones; c. Timelines; 6. Other matters; 7. Closure of the meeting. B. Organization of work 15. The meeting was held in plenary to discuss the information requirements and areas for update of the guidance document. The first part of the meeting was dedicated to presentations by the monitoring programmes on ongoing activities relevant to the newly listed POPs that are to be addressed in the GMP guidance document. The following days have been allocated to brainstorming on the inclusion of the newly listed POPs in the GMP guidance document and to the development of a workplan for updating the guidance document to enable its submission for consideration at COP-9 in C. Attendance 16. The meeting was attended by the following invited experts: Ms. Maria Tominaga (Brazil), Mr. Tom Harner (Canada), Mr. Minghui Zheng (China), Ms. Kateřna Šebková and Ms. Jana Klanova (Czech Republic), Mr. Rainer Malisch and Ms. Karin Malisch (Germany), Mr. Yasuyuki Shibata (Japan), Mr. Vincent Odongo Madadi (Kenya), Mr. Mohammed Kabriti (Morocco), Mr. Ramon Guardans (Spain), Ms. Heidelore Fiedler (Sweden), Ms. Alejandra Torre (Uruguay). 17. Other experts involved in monitoring work within programmes contributing to the GMP attended the meeting: Ms. Jana Borůvková, Mr. Richard Hůlek, Ms. Petra Přibylová, Ms. Petra Růžičková, and Mr. Petr Kukučka (all RECETOX), and Mr. Gilberto Fillmann (Federal University of Rio Grande, Brazil). 18. The meeting was also attended by observers: Ms. Zhang Caili and Mr. Zheng Zhe (China), Mr. Jeffrey D. Herrick (United States). 19. Ms. Katarina Magulova and Ms. Ana Witt, Secretariat of the Basel, Rotterdam and Stockholm Convention, participated in the meeting. IV. Experiences from monitoring programmes in sampling and analyzing the newly listed POPs in core matrices and other media 20. Presentations of ongoing monitoring activities relevant to the newly listed POPs from different ongoing activities and programmes have been given by: Mr. Yasuyuki Shibata (NIES, Japan) on the development and application of new POPs monitoring in Japan, Ms. Heidi Fiedler (MTM Orebro, Sweden) on the experiences and results of PFAS in UNEP/GEF GMP2 projects and on the third round of the global interlaboratory assessment, Mr. Tom Harner (Environment Canada) on monitoring of new POPs in WEOG and GAPS air monitoring programs, Mr. Petr Kukučka (RECETOX) on monitoring newly listed POPs within MONET, Mr. Rainer Malisch (CVUA Freiburg, Germany) on considerations for monitoring of newly listed 3

4 POPs in human milk, and Mr. Gilberto Fillmann (FURG, Brazil) on relevant monitoring activities in the Latin American Passive Atmospheric Sampling Network (LAPAN). The information relevant to the inclusion of the newly listed POPs in the GMP guidance document is summarized in sections A-F below. 21. Ms. Jana Klánová (RECETOX) introduced several relevant global and European projects and initiatives which can contribute to the ongoing work on the GMP, among which the Global Earth Observation System of Systems (GEOSS), ERA-PLANET and ERA-NET network, and the European Human Biomonitoring Initiative (HBM4EU) led by the German Environment Agency. RECETOX is leading the GEOSS initiative Global Observation System for Persistent Organic Pollutants (GOS4POPS) as part of GEOSS. There is a need for involvement of global coordination group representatives from the regions in the steering committee to help in harmonizing activities and bringing together the relevant outputs of these processes towards benefitting the ongoing work on the GMP. Resources from all these ongoing processes can and should be leveraged to contribute to the GMP. 22. Mr. Richard Hůlek (RECETOX) gave a short report on the GMP data warehouse including statistics of website traffic and visibility, visitor data etc. A. Hexachlorobutadiene (HCBD) 23. HCBD is measured in air in the Arctic at Alert and in the Great Lakes. It is suspected that sampling rates may be underestimated at windy locations in the Arctic. New XAD-passive sampler housings with wind-dampening spoilers are under development to replace traditional XAD-passive samplers to eliminate the wind effect at Arctic sites. In Japan, HCBD is monitored by a thermal desorption method and was found in ambient air at similar uniform levels. 24. Due to its volatility, HCBD may be subject to breakthrough in high volume air samples. Concentrations measured in ambient air may depend on the extent of breakthrough. Long-term exposure of samplers would be needed to be represented by a time series of short-term measurements. 25. From the analytical point of view, HCBD does not pose challenges and can be co-analysed with other organochlorine pesticides. HCBD was already included in the UNEP-coordinated interlaboratory assessment of 2016/2017. Due to high volatility, HCBD might partly be lost during clean-up process. In thermal desorption method, which does not have clean-up step, break though may be a problem particularly under high temperature / humidity condition. In both cases, recovery can be corrected by the use of 13C-labeled HCBD as surrogate (needs GC/high resolution MS) while the use of other surrogate chemical needs prior validation of analytical condition. B. Pentachlorophenol and its salts and esters (PCP) 26. Pentachlorophenol is routinely monitored in pesticide analysis but not in ambient air monitoring programmes. Instead, monitoring of pentachloroanisole (PCA) is reported in ambient air. Low volatility of the chemical results in breakthrough and equilibrium issues for both active and passive sampling, therefore the need to assess performance of high volume and passive air samplers. In Japan active sampling is used for PCA and PCP without any problem (due to low volatility). PCA and related compounds are commonly reported, namely PCAN pentachloraniline and PCTA pentachlorothioanisole. During the intersessional period, analytes shall be defined for ambient air as a core matrix. 27. PCP does not bioaccumulate and thus cannot be found in human milk. The risk profile on PCP notes that while PCP undergoes rapid biotransformation, its metabolite PCA is largely found in humans and biota. When the POPs Review Committee evaluated the Annex D information on PCP it decided that, while the PCP molecule itself does not meet all the screening criteria specified in Annex D, PCP and its salts and esters, taking into account the transformation product PCA, do meet the screening criteria specified in Annex D. PCP was used for wood preservative as well as herbicides in Japan and can still be found in wildlife samples in Japan in addition to PCA. C. Polychlorinated naphthalenes (PCNs) 28. Di- through octachlorinated naphthalenes are listed in Annex A. PCNs are monitored in ambient air as part of GAPS, in Japan, and within the MONET programme. 4

5 29. PCNs in air originate from historical emissions related to PCN technical mixtures (equipment releases and secondary sources) and new emissions from combustion processes. It is difficult to detect PCNs in air due to low levels and there are analytical challenges especially for combustion PCNs. Ambient air concentrations of PCNs are typically one order of magnitude lower than those measured for PCBs. Monitoring of this class of chemicals should include urban sites where PCN levels are typically higher (similar situation as for BDE-209). It is important to include PCNs created as by-products of combustion processes from the technical mixture PCNs to assess new/current sources to air. 30. Some programmes use technical mixtures as standards, some use standards for particular congeners. Different approaches for reporting also exist e.g. total PCN amount vs. reporting of few congeners only. The selection of congeners also differs from programme to programme. More research is needed on various approaches as well as available standards to enable the definition of a common set of congeners as recommended analytes for the GMP. D. Decabromodiphenyl ether (Deca-BDE) 31. BDE-209 is monitored within most programmes. In the Arctic, air concentrations measured at Alert have decreased after about 2007 and many samples are showing concentrations similar to the blanks. Information from the Great Lakes Basin showed a slow declining trend at Point Petre but is starting to decline relatively quickly at the more remote site of Burnt Island. BDE-209 is expected to be mostly found on particles and is likely to be removed from the atmosphere via deposition making it more difficult to undergo LRT to the more remote sites such as Burnt Island. In Japan and Spain, BDE-209 was shown to be the dominant PBDE congener detected in air. 32. In respect to its detection, the compound has high blank, high detection limits, and low detection frequencies, e.g. 40% detection under GAPS in 2014, EMEP sites (n=5) report BDE-209 but concentrations below LOD for most samples. There is uncertainty in temporal trends determined from data that is close to detection.concentrations in urban ambient air typically are one order of magnitude higher than background concentrations. Therefore air monitoring of this substance should include urban sites. 33. Regarding the analytical aspects, the compound tends to degrade during analysis and requires special injection methods and columns (e.g. short GC column). 34. In human milk, BDE-209 can be co-analysed with the other PBDEs in a different GC/MC run (shorter column for BDE-209). The extraction and cleanup of the sample is the same, but two separate fractions are to be analyzed - one for PBDEs and other for BDE-209. E. Short-chain chlorinated paraffins (SCCPs) 35. Data availability on SCCPs is currently low but increasing. Their analysis is difficult, with issues in cost due to the need of multiple analytical runs of the same sample and availability of analytical standards and calibration methods. The need to collaborate with expert labs on such analytically complex compounds has been highlighted. 36. SCCPs were screened in air samples from Alert using the Tomy et al. (2000) method. Environment Canada is planning to move to a different analytical method, i.e. QE GC Orbitrap MS-MS in full scan set to 60 K resolution; following the ISO water quality method for SCCPs (Geiss et al, Accred. Qual. Assur. 17 (2012) 15-25) and results will be reported in total SCCP concentrations. 37. Under the Arctic Council s Arctic Monitoring and Assessment Program, a mini-round-robin is being planned for early 2018 between the labs analyzing for SCCPs at the Alert (Canada) station and the Zeppelin station (Svalbard) to ensure data comparability. The round-robin will include exchange of cleaned up air samples to compare results. 38. SCCP analytical method is in development in Japan as well. An LC/MS method for SCCP and MCCP in water, sediments and wildlife is documented in the White Book (2004), it is open to public, but not approved due to presence of interferences from MCCP. Another method based on GC/NICI-hrMS or GC/NICI-TOF for environmental samples has been documented (Dr Takasuga, Shimadzu Techno Research) for the analysis of SCCPs in wildlife samples. Issues to be improved/harmonized include (1) Quantification method / standards; (2) Identification of major interferences and procedures to remove them; (3) Definition of SCCP: C10 to C13, to determine range of chlorine number. 5

6 39. In human milk the use of the screening method has been reported with results expressed as the sum of short and medium chain CPs. 40. Among the five newly listed chemicals within the scope of the update process, the approach on how to handle SCCPs in the frame of the GMP is the most challenging. There are ongoing activities and opportunities to leverage resources from e.g. the GEF GMP2 projects in coordination with the EU ERANET project and ongoing national activities such as in Japan. Activities in the intersessional period to address this set of chemicals should include an inventory of ongoing relevant activities and approaches to analyzing SCCPs, expert discussion in the frame of the GMP and identification of steps for establishing analytical methods. Further ongoing expert processes have been reported to be in place for monitoring of perfluorinated substances other than PFOS in water; these are important information exchange platforms that will inform and contribute to the GMP upon listing of these substances in the Convention. In particular, there will be an increased need for specialized laboratories (in particular substance groups such as the fluorinated POPs and SCCPs). 41. Ms. Alejandra Torre (LATU, Uruguay) informed of the steering committee meeting for the UNEP/GEF GMP2 projects, which will be held in February 2018 and could offer a platform for the steering committee experts to discuss further this issue and other relevant aspects, including for other POPs under the scope of the GMP guidance update. F. Chemicals under review by the POPs Review Committee 42. According to information to date, dicofol seems to be difficult to monitor in air and in human matrices. The stable degradation product is reported in air, but more research on analytical aspects and detection limits is needed. In biological samples (fish), dicofol has not been quantified so far. In addition, since dicofol is sensitive to alkali and heat, transformation to p,p -dichlorobenzophenone may occur in the injection system. 43. As for PFOA and PFHxS, there are ongoing expert processes on fluorinated substances such as Aqua-GAPS, the EU biomonitoring programme, and others that can inform the work on these substances within the GMP. For passive air monitoring, SIP is preferred, but both substances can be measured in XAD as well. In humans, PFOA and PFHxS are found in higher concentrations in blood (similar to PFOS) but can be analysed in human milk as well although at low concentrations. It was also noted that further relevant information is still expected to come from the ongoing review process by the POPs Review Committee, in particular on aspects relevant to the chemical identity of related substances that would be covered in the listing and thus subject to monitoring. V. Brainstorming on the inclusion of the newly listed POPs in the GMP guidance document A. General issues 44. A lot of experience has been generated throughout the two phases of implementation of the GMP, and the guidance document needs to reflect concretely the present situation and include lessons learned and conclusions and recommendations of the second global report throughout the various chapters and sections of the guidance as relevant. B. Strategic considerations 45. Strategic considerations for future monitoring in particular for chemicals with levels around LOQ/LOD will need to be addressed in the guidance. The guidance document currently lacks such strategic considerations for sustainable monitoring on aspects such as frequency of sampling, practical and efficient use of resources for monitoring and eventual prioritization of substances/analytes. 46. It will be important that the guidance identifies which analytes to look for and with which limit of quantification, also noting that compounds to look for in human matrices may be different than air etc. C. Substances to be monitored 47. Most newly listed POPs are highly volatile and could be sampled jointly with a different set-up (sorbent e.g. XAD, SIP or combined, and shorter time) as the present POPs. For human biomonitoring, more 6

7 sample volume will be needed since several substance groups will require separate analytical approaches/runs. In a revised SOP within the UNEP/GEF GMP 2 projects, these aspects are already accounted for. 48. The table below reflects the current state of knowledge as to the analytes to be included in the GMP. Details pertaining to the further work to address knowledge gaps identified in square brackets in the table are included in section VI below. POPs listed in 2015 Air Human Milk Human Blood Water PCNs [PCNs] [PCNs] [PCNs] - HCBD HCBD HCBD HCBD - PCP [PCP, PCA] PCA PCA PCP POPs listed in 2015 DecaBDE BDE-209 BDE-209 BDE SCCP (C 10 -C 13 ) alkanes [SCCPs] [SCCPs] [SCCPs] - Chemicals under review Dicofol [Dicofol] PFOA PFOA [PFOA] PFOA PFOA PFHxS PFHxS PFHxS PFHxS PFHxS 49. The substantive areas requiring update are presented chapter by chapter in section VI of this report (see section I of the workplan). VI. Way forward and workplan for updating the GMP guidance document 50. The following workplan to update the GMP guidance document has been agreed upon. I. Areas for updates and responsibilities Chapter Activity Lead / contributors 1. Background and objectives NEW Approach to sustainable monitoring Updates to reflect current status from the second phase including lessons learned, summarized from second phase global report, incl. relevant conclusions and recommendations (NOTE: For the latter, to be reflected throughout the guidance in each chapter as relevant) NEW (sub-)chapter on sustainability considerations incl. capacity building considerations Secretariat in consultation w experts as needed Katerina Sebkova with regional coordinators 7

8 2. Substances to be monitored 3. Statistical considerations PCNs - define the congeners so that they cover the technical mixtures and unintentional generation Confirm and provide ref. for PCP / PCA in air SCCP intersessional work will aim at defining the approach on how to handle SCCP in the GMP The issue shall be considered in the frame of the GEF GMP2 projects, coordinated with ERANET, ongoing activities in Japan and other relevant activities, and provide the following: - inventory of ongoing relevant activities and approaches to analyzing SCCPs - expert discussion - identification of steps to establish analytical methods Dicofol - Stable degradation/breakdown product monitored in air; verify occurrence in humans and biota PFOA, PFHxS to be considered by experts working on water chapter and on air chapter; other media as well Add overarching analytical aspects from Ch 5 and Annex 1; Reflect data quality criteria from the implementation plan To be revised together with the technical note and a simple practical annex developed based on current practice Minghui Zheng, Rainer Malisch, Heidi Fiedler, Yasuyuki Shibata, Tom harner, Katerina Sebkova/Petr Kukučka Tom Harner, Yasuyuki Shibata to check what is available/provide reference Rainer Malisch, Katerina Sebkova/Jana Klanova, Yasuyuki Shibata, Minghui Zheng, Tom Harner, Derek Muir, Gregg Tomy Tom Harner, Heidi Fiedler to provide reference; Secretariat to look into RP Katerina Sebkova/Jana Klanova, Derek Muir, Heidi Fiedler, Tom Harner, Ramon Guardans Heidi Fiedler Katerina Sebkova 4.1. Air Structure does not need to change; Special considerations for PFOS to be expanded to cover other relevant new POPs; Include information on model used to estimate sampling rates global metspace model; intercallibration exercise to be added under comparability section; Explain partition coefficient approach; Tables with travel distances to be updated to include new POPs; Reporting units, data treatment. Tom Harner, Jana Klanova, Gilberto Fillmann, Yasuyuki Shibata, Minghui Zheng, Matt McLeod, AlejandraTorre 8

9 4.2. Human matrices Analytical considerations for the newly listed POPs add further new POPs according to information available; Provide guidance to have larger sample volumes as the no. of analytes increases; Provide recommendations on which analytes to look for and which should be omitted e.g. PCP (as opposed to PCA) etc. Ethics need to highlight and provide template. Update information on new programmes, provide information on reliable biomonitoring programs that may supply data for the future, incl. reference to EU biomonitoring programme Human blood as a general medium for human biomonitoring Secretariat w input from Rainer Malisch, Heidi Fiedler, Katerina Sebkova, Linda Linderholm 4.3. Water The chapter does not need much amendment; Add lessons learned from second phase; Include information on AQUAGPAS project; elaborate on new developments e.g. samplers and bring in the new chemicals PCP, PFOA, PFHxS; Provide guidance on how to capture the cruises in the regional reports as more information on water will become available in the regions 4.4. Other media NEW subchapter to be developed using conclusions and recommendations from the global report Global network involving RECETOX, Env Canada, China Katerina Sebkova/Jana Klanova, Derek Muir, Heidi Fiedler, Ramon Guardans Ramon Guardans, Yasuyuki Shibata, Minghui Zheng, Heidi Fiedler, Vincent Madadi, Katrin Borga 5. Analytical methodology Add the new chemicals in the tables describing the instrumentation, costs etc. Move overarching issues to Chapter 2 Data treatment - include parts of it in the media specific chapters (Chapter 4) After first draft of Ch 4 is finalized 6. Data handling Focus on practical guidance and reflect current practice. Theoretical aspects to be removed. Katerina Sebkova and regional coordinators 7. Outline of regional reports No major chg; section 7.2. to be updated based on EE; consideration for regional transport included from Annex 2 Secretariat 8. ESB Minor updates Yasuyuki Shibata, Katerina Sebkova/Jana Klanova and other relevant experts Annex 1 Annex 2 Annex 1 to be revised, amended and concise summary to be put in Chapter 2, substance-specific Annex 2 to include the annotated outline of the global report. The outline shall be revised based on EE and conclusions and recommendations of the coordination group. Put consideration for regional transport into the outlines of regional reports in Chapter 7. Heidi Fiedler Secretariat 9

10 Annex 3, 4 To be updated in consultation w AMAP and WHO; Milk sampling SOP from GEF GMP2 projects to be included here. Secretariat in consultation with relevant partners Annex 5 SOP for air monitoring to be updated Tom Harner, Alejandra Torre Annex 6 Keep as it is and update with the new chemicals Tom Harner Annex 7 Drop - Technical note To be revised along w Chapter 3 Statistical considerations Katerina Sebkova II. Case study To be updated based on last set of data; to reflect most up to date information from second global report; mention wealth of data available to date Katerina Sebkova, Ramon Guardans II. Timelines Activity Deadline Secretariat to draft the report of the expert meeting 17 November 2017 Review of and comments on the meeting report by the experts 24 November 2017 Leads for each chapter/section of the guidance document to initiate intersessional work and request input from contributors Each lead to send interim updated draft chapters/sections for review by the expert group 30 November February 2018 Expert to provide comments on the draft chapters 15 March 2018 Intersessional work finalized and updated chapters/sections submitted to the Secretariat for compilation Meeting of the regional organization groups and global coordination group to consider the draft updated guidance 16 April May 1 June 2018 VII. Date and venue of the 2018 ROG and GCG meeting 51. The tentative dates of the 2018 meeting of the regional organization groups and global coordination group have been established as 28 May 1 June. The meeting venue will be selected on the base of a cost assessment of proposed possible locations. VIII. Closure of the Meeting 52. Following the customary exchange of courtesies, the meeting was closed at 13:00 on Thursday 9 November

11 Annex: Milestones and timelines for the development of 3rd GMP phase monitoring reports Milestones Meetings of the COP 1 st ½ 2017 COP 8 2 nd ½ st ½ nd ½ st ½ 2019 COP9 2 nd ½ st ½ nd ½ 2020 May 2021 COP1 0 Air monitoring activities Water monitoring activities Human monitoring Updating of Guidance after listing new POPs (expert group) X updated Meetings of the global coordination group (GCG) X X X X Meetings of the ROGs X x X ROGs to check availability of existing programmes for GMP Phase 3 ROGs to identify additional programmes to fill the geographic gaps ROGs to identify programmes to contribute baseline for new POPs GCG to evaluate further needs for capacity enhancement Establish arrangements to receive data sets ROGs to establishing drafting team ROGs collecting all data and information to be used for drafting ROGs to evaluate quality of data sets and process data ROGs to finalize the first draft of the regional monitoring reports Draft regional monitoring report submitted for regional comments ROGs to revise the regional reports according to comments Finalization of the regional monitoring reports and submission to SSC Reports considered and welcomed at COP 10 GCG to develop the global monitoring report Full effectiveness evaluation by the EEG GMP global report and second EE report considered at COP-11 2 nd ½ COP11 11